 |
answer text |
<p>The information requested is not held centrally.</p><p> </p><p>In 2013, NHS England
published a policy on the use of Sapropterin for the management of Phenylketonuria
(PKU) during pregnancy:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf"
target="_blank">https://www.england.nhs.uk/wp-content/uploads/2013/04/e12-p-a.pdf</a></p><p>
</p><p>NHS England has now received a Preliminary Policy Proposal for the use of Sapropterin
in the management of PKU for adults and children, as new evidence has now been published
to support its use. This was considered by the Clinical Panel this month where it
was agreed that NHS England will need to further review the evidence. NHS England
will be working with the National Institute for Health and Care Excellence to agree
the best approach to this and whether the policy should subsequently be reviewed.
The NHS England process for development of Clinical Policies can be found here:</p><p>
</p><p><a href="https://www.england.nhs.uk/publication/specialised-commissioning-service-development-policy-and-process/"
target="_blank">https://www.england.nhs.uk/publication/specialised-commissioning-service-development-policy-and-process/</a></p><p>
</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/"
target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p>
|
|
